The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

FANCB  -  Fanconi anemia, complementation group B

Homo sapiens

Synonyms: FA2, FAAP90, FAAP95, FAB, FACB, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of FANCB


Psychiatry related information on FANCB

  • Our case has many characteristics in common with the second type of t-AML such as: exposure to topoisomerase II active agents (idarubicin (IDA), mitoxantrone (MITOX), etoposide (VP16)), M4 FAB subtype, a latency period of 39 months and absence of a preleukemic phase [6].
  • FAB showed the presence of various species and of these, that at m/z 305 increased in abundance with reaction time in immediately lyophilized set of samples only [7].
  • A controlled evaluation of a school-based intervention to promote physical activity among sedentary adolescent females: project FAB [8].
  • Psychometric characteristics of the Spanish version of the FAB questionnaire [9].

High impact information on FANCB

  • The cases in these latter two groups tended to have myelomonocytic (FAB M4) morphology and to express monocyte surface antigens [10].
  • After lysis in a Brij 58-polyethylene glycol medium, PtK1 cells are permeable to small molecules, such as erythrosin B, and to proteins, such as rhodamine-labeled FAB, myosin subfragment-1, and tubulin [11].
  • Patients with more than 5% blasts in day-15 bone marrow or with FAB M3 were not included [12].
  • We determined whether distinct gene expression profiles were associated with specific FAB and cytogenetic groups [13].
  • Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype [13].

Chemical compound and disease context of FANCB

  • Factors at diagnosis associated with the subsequent development of central nervous system leukemia were elevated leukocyte count, serum lysozyme and lactate dehydrogenase, extramedullary infiltration including splenomegaly, and monocytic (FAB M4 or M5a) morphology [14].
  • Surface-induced dissociation (SID) has been used to produce daughter ion spectra of small protonated peptides generated by fast atom bombardment (FAB) [15].
  • The authors report on the preliminary results of an ongoing phase II trial whereby the combination of the new DNA hypomethylating agent, 5-Aza-deoxycytidine (DAC), plus daunorubicin was given as first-line induction therapy to non-pretreated patients with acute myeloid leukemia (except FAB M3) [16].
  • Acute monocytic leukemia with chloroacetate esterase positivity: FAB M4 or M5 [17]?
  • Thirty-two evaluable patients with advanced measurable gastric adenocarcinoma were treated with a combination of 5-fluorouracil, adriamycin, and BCNU (FAB) [18].

Biological context of FANCB


Anatomical context of FANCB

  • Ph+ ALL is an aggressive form of acute leukemia that frequently presents in older children with a high leukocyte count, FAB L2 morphology, and a pseudodiploid karyotype, and becomes multidrug-resistant early [24].
  • First CR length was also negatively affected by early CNS involvement, morphological FAB L3 subtype, and B-cell (Smlg+) leukemia, but these features were significantly associated with a high WBC count [25].
  • The response of leukemic progenitor cells to HMW-BCGF or LMW-BCGF did not correlate with sex, age, disease status, FAB morphology, WBC at diagnosis, or immunophenotype [26].
  • All patients with 8;21 (or C/G) translocation had a low neutrophil AP score and leukemic cells with maturation (M2 of FAB classification) in the bone marrow [27].
  • Twenty-six patients with inv(16)(p13q22) or del(16)(q22) in association with acute myelomonocytic leukemia (AMML-M4, FAB classification), and abnormal marrow eosinophils have been treated at this institute [28].

Associations of FANCB with chemical compounds

  • The antigen was purified, and characterized by compositional analysis, fast atom bombardment (FAB) mass spectrometry, sequential exoglycosidase treatments, methylation analysis, and (1)H-nuclear magnetic resonance spectroscopy, proving to be isoglobotetraosylceramide (IsoGb4) [29].
  • There was a significantly higher response rate observed for FAB (40%) compared with doxorubicin (13%) among the 145 measurable-disease patients [30].
  • Acute promyelocytic leukemia (FAB M3) is distinguished by the presence of the t(15;17) and clinical response to all-trans retinoic acid (RA) treatment [31].
  • Furthermore, among the AML patients both the percentage of the choline-containing phosphoglyceride fraction (PC) which is alkyl linked and the nmoles alkyl-PC/10(6) cells differ significantly by FAB subtype [32].
  • Gas chromatography analysis revealed only glucose and FAB-mass spectrometric analysis showed only heptaglucoside and no noncarbohydrate molecules [33].

Other interactions of FANCB

  • Presently 6 different fumonisins (FB1, FB2, FB3, FB4, FA1 and FA2) have been identified and characterized [34].

Analytical, diagnostic and therapeutic context of FANCB


  1. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Borrow, J., Shearman, A.M., Stanton, V.P., Becher, R., Collins, T., Williams, A.J., Dubé, I., Katz, F., Kwong, Y.L., Morris, C., Ohyashiki, K., Toyama, K., Rowley, J., Housman, D.E. Nat. Genet. (1996) [Pubmed]
  2. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Borrow, J., Goddard, A.D., Sheer, D., Solomon, E. Science (1990) [Pubmed]
  3. The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts. Testa, U., Grignani, F., Samoggia, P., Zanetti, C., Riccioni, R., Lo Coco, F., Diverio, D., Felli, N., Passerini, C.G., Grell, M., Pelicci, P.G., Peschle, C. J. Clin. Invest. (1998) [Pubmed]
  4. A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Pegoraro, L., Palumbo, A., Erikson, J., Falda, M., Giovanazzo, B., Emanuel, B.S., Rovera, G., Nowell, P.C., Croce, C.M. Proc. Natl. Acad. Sci. U.S.A. (1984) [Pubmed]
  5. Chromosome pattern in childhood acute nonlymphocytic leukemia (ANLL). Kaneko, Y., Rowley, J.D., Maurer, H.S., Variakojis, D., Moohr, J.W. Blood (1982) [Pubmed]
  6. Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia. Todisco, E., Testi, A.M., Avvisati, G., Moleti, M.L., Cedrone, M., Cimino, G., Mancini, F., Amadori, S., Mandelli, F. Leukemia (1995) [Pubmed]
  7. Biosynthesis of melanin from dopamine. An investigation of early oligomerization products. Bertazzo, A., Costa, C., Allegri, G., Seraglia, R., Traldi, P. Rapid Commun. Mass Spectrom. (1995) [Pubmed]
  8. A controlled evaluation of a school-based intervention to promote physical activity among sedentary adolescent females: project FAB. Jamner, M.S., Spruijt-Metz, D., Bassin, S., Cooper, D.M. The Journal of adolescent health : official publication of the Society for Adolescent Medicine. (2004) [Pubmed]
  9. Psychometric characteristics of the Spanish version of the FAB questionnaire. Kovacs, F.M., Muriel, A., Medina, J.M., Abraira, V., Sánchez, M.D., Jaúregui, J.O. Spine. (2006) [Pubmed]
  10. Heterogeneity of clonogenic cells in acute myeloblastic leukemia. Sabbath, K.D., Ball, E.D., Larcom, P., Davis, R.B., Griffin, J.D. J. Clin. Invest. (1985) [Pubmed]
  11. A permeabilized cell model for studying cell division: a comparison of anaphase chromosome movement and cleavage furrow constriction in lysed PtK1 cells. Cande, W.Z., McDonald, K., Meeusen, R.L. J. Cell Biol. (1981) [Pubmed]
  12. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Lehrnbecher, T., Zimmermann, M., Reinhardt, D., Dworzak, M., Stary, J., Creutzig, U. Blood (2007) [Pubmed]
  13. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Pellagatti, A., Cazzola, M., Giagounidis, A.A., Malcovati, L., Porta, M.G., Killick, S., Campbell, L.J., Wang, L., Langford, C.F., Fidler, C., Oscier, D., Aul, C., Wainscoat, J.S., Boultwood, J. Blood (2006) [Pubmed]
  14. Central nervous system involvement in acute nonlymphocytic leukemia. A prospective study of adults in remission. Peterson, B.A., Brunning, R.D., Bloomfield, C.D., Hurd, D.D., Gau, J.A., Peng, G.T., Goldman, A.I. Am. J. Med. (1987) [Pubmed]
  15. Surface-induced dissociation of protonated peptides: implications of initial kinetic energy spread. Cole, R.B., LeMeillour, S., Tabet, J.C. Anal. Chem. (1992) [Pubmed]
  16. Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Schwartsmann, G., Fernandes, M.S., Schaan, M.D., Moschen, M., Gerhardt, L.M., Di Leone, L., Loitzembauer, B., Kalakun, L. Leukemia (1997) [Pubmed]
  17. Acute monocytic leukemia with chloroacetate esterase positivity: FAB M4 or M5? Miller-Canfield, P., Dubell, J., Schumacher, H.R. Am. J. Clin. Pathol. (1993) [Pubmed]
  18. 5-fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer. Lopez, M., Perno, C.F., Di Lauro, L., Papaldo, P. Cancer Chemother. Pharmacol. (1984) [Pubmed]
  19. No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndrome gene NBS1 by DNA hyper-methylation in sporadic childhood leukaemia. Meyer, S., White, D.J., Will, A.M., Eden, T., Sim, A., Brown, R., Strathdee, G. Br. J. Haematol. (2006) [Pubmed]
  20. Fanconi anaemia complementation group B presenting as X linked VACTERL with hydrocephalus syndrome. Holden, S.T., Cox, J.J., Kesterton, I., Thomas, N.S., Carr, C., Woods, C.G. J. Med. Genet. (2006) [Pubmed]
  21. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. Cuneo, A., Ferrant, A., Michaux, J.L., Boogaerts, M., Demuynck, H., Van Orshoven, A., Criel, A., Stul, M., Dal Cin, P., Hernandez, J. Blood (1995) [Pubmed]
  22. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Massey, G.V., Zipursky, A., Chang, M.N., Doyle, J.J., Nasim, S., Taub, J.W., Ravindranath, Y., Dahl, G., Weinstein, H.J. Blood (2006) [Pubmed]
  23. The contribution of cytochemistry and immunophenotyping to the reproducibility of the FAB classification in acute leukemia. Browman, G.P., Neame, P.B., Soamboonsrup, P. Blood (1986) [Pubmed]
  24. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. Crist, W., Carroll, A., Shuster, J., Jackson, J., Head, D., Borowitz, M., Behm, F., Link, M., Steuber, P., Ragab, A. Blood (1990) [Pubmed]
  25. Adolescent and adult acute lymphoblastic leukemia: prognostic features and outcome of therapy. A study of 293 patients. Baccarani, M., Corbelli, G., Amadori, S., Drenthe-Schonk, A., Willemze, R., Meloni, G., Cardozo, P.L., Haanen, C., Mandelli, F., Tura, S. Blood (1982) [Pubmed]
  26. B-cell growth factor receptor expression and B-cell growth factor response of leukemic B cell precursors and B lineage lymphoid progenitor cells. Uckun, F.M., Fauci, A.S., Heerema, N.A., Song, C.W., Mehta, S.R., Gajl-Peczalska, K., Chandan, M., Ambrus, J.L. Blood (1987) [Pubmed]
  27. In vivo and in vitro activity of neutrophil alkaline phosphatase in acute myelocytic leukemia with 8;21 translocation. Kamada, N., Dohy, H., Okada, K., Oguma, N., Kuramoto, A., Tanaka, K., Uchino, H. Blood (1981) [Pubmed]
  28. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Holmes, R., Keating, M.J., Cork, A., Broach, Y., Trujillo, J., Dalton, W.T., McCredie, K.B., Freireich, E.J. Blood (1985) [Pubmed]
  29. A monoclonal antibody that induces neuronal apoptosis binds a metastasis marker. Zhong, L.T., Manzi, A., Skowronski, E., Notterpek, L., Fluharty, A.L., Faull, K.F., Masada, I., Rabizadeh, S., Varsanyi-Nagy, M., Ruan, Y., Oh, J.D., Butcher, L.L., Bredesen, D.E. Cancer Res. (2001) [Pubmed]
  30. Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. Levi, J.A., Fox, R.M., Tattersall, M.H., Woods, R.L., Thomson, D., Gill, G. J. Clin. Oncol. (1986) [Pubmed]
  31. A ribozyme which discriminates in vitro between PML/RAR alpha, the t(15;17)-associated fusion RNA of acute promyelocytic leukemia, and PML and RAR alpha, the transcripts from the nonrearranged alleles. Pace, U., Bockman, J.M., MacKay, B.J., Miller, W.H., Dmitrovsky, E., Goldberg, A.R. Cancer Res. (1994) [Pubmed]
  32. Ether-linked phosphoglyceride content of human leukemia cells. Chabot, M.C., Greene, D.G., Brockschmidt, J.K., Capizzi, R.L., Wykle, R.L. Cancer Res. (1990) [Pubmed]
  33. Isolation of a yeast heptaglucoside that inhibits monocyte phagocytosis of zymosan particles. Janusz, M.J., Austen, K.F., Czop, J.K. J. Immunol. (1989) [Pubmed]
  34. Fumonisin exposure to Kansans through consumption of corn-based market foods. Rumbeiha, W.K., Oehme, F.W. Veterinary and human toxicology. (1997) [Pubmed]
  35. Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification. Hébert, J., Cayuela, J.M., Daniel, M.T., Berger, R., Sigaux, F. Blood (1994) [Pubmed]
  36. Novel SH3 protein encoded by the AF3p21 gene is fused to the mixed lineage leukemia protein in a therapy-related leukemia with t(3;11) (p21;q23). Sano, K., Hayakawa, A., Piao, J.H., Kosaka, Y., Nakamura, H. Blood (2000) [Pubmed]
  37. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. Lee, E.J., Petroni, G.R., Schiffer, C.A., Freter, C.E., Johnson, J.L., Barcos, M., Frizzera, G., Bloomfield, C.D., Peterson, B.A. J. Clin. Oncol. (2001) [Pubmed]
  38. Mass spectrometry in the search for uremic toxins. Niwa, T. Mass spectrometry reviews. (1997) [Pubmed]
WikiGenes - Universities